Ge Healthcare Technologies INC 8-K filings

GE HealthCare Technologies Inc. has announced a strategic restructuring of its business segments, combining Imaging and Advanced Visualization Solutions into a new Advanced Imaging Solutions (AIS) segment, and has provided recast unaudited historical financial information.

GE HealthCare announced robust second quarter 2026 financial results, highlighted by record organic orders growth and a significant increase in backlog, while reaffirming full-year guidance.

GE HealthCare Technologies Inc. announced preliminary Q2 2026 financial results showing revenue growth and better-than-expected EPS, alongside the departure of CFO Jay Saccaro.

GE HealthCare Technologies Inc. held its annual meeting on May 7, 2026, where stockholders elected directors, approved executive compensation, and ratified auditor appointments, with subsequent board leadership changes.

GE HealthCare reported a 7.4% revenue increase for Q1 2026, driven by strong performance in key segments, but lowered its full-year profit and free cash flow outlook due to increased inflation.

GE HealthCare Technologies Inc. announced the appointment of Kevin A. Lobo, Chair and CEO of Stryker Corporation, to its Board of Directors, while two current directors will not seek re-election.

GE HealthCare Technologies Inc. has entered into a new 364-day senior unsecured revolving credit agreement for $0.5 billion, replacing its previous facility.

GE HealthCare reported strong fourth quarter and full year 2025 financial results, exceeding topline and EPS expectations, and provided optimistic 2026 guidance.

GE HealthCare Technologies Inc. has issued $1.25 billion in senior notes and secured a $750 million term loan to fund its acquisition of Intelerad Medical Systems.

GE HealthCare Technologies Inc. has priced an underwritten offering of $1.25 billion in senior notes to partially fund the acquisition of Intelerad Medical Systems.

GE HealthCare Technologies Inc. announced robust third-quarter 2025 financial results, driven by strong organic orders and revenue growth, despite tariff impacts on margins and earnings.

GE HealthCare announced solid second quarter 2025 financial performance with increased revenue and earnings, leading to an upward revision of its full-year 2025 financial guidance.

GE HealthCare Technologies Inc. announced the immediate resignation of Lloyd W. Howell, Jr. from its Board of Directors, stating no disagreement over company operations or policies.

GE HealthCare Technologies Inc. has successfully issued $1.5 billion in new senior unsecured notes across two series, maturing in 2031 and 2035, to enhance its financial flexibility.

GE HealthCare Technologies Inc. announced the successful pricing of an underwritten public offering totaling $1.5 billion in aggregate principal amount of senior notes, maturing in 2031 and 2035.

GE HealthCare Technologies Inc. announced the results of its annual meeting, where stockholders re-elected all 10 director nominees, approved executive compensation, and ratified Deloitte & Touche LLP as independent auditor for 2025.

GE HealthCare announces positive first quarter 2025 financial results with revenue growth and increased earnings, while also updating full-year guidance and authorizing a significant share repurchase program.

GE HealthCare Technologies Inc. has secured new revolving credit facilities totaling $3.5 billion, replacing previous agreements to optimize its financial structure.

GE HealthCare announces positive Q4 and full year 2024 financial results with revenue and earnings growth, and introduces its full-year 2025 financial guidance.

GE HealthCare Technologies Inc. has entered into a new $1.0 billion 364-day revolving credit agreement, replacing its previous facility that matured on the same day.

GE HealthCare hosted its 2024 Investor Day, reaffirming its 2024 financial outlook, outlining medium-term targets, and announcing a 17% increase in its quarterly cash dividend.

GE HealthCare Technologies Inc. has announced a secondary offering of 13,281,302 shares of its common stock, with no proceeds going to the company.

GE HealthCare has realigned its reporting segments, moving Image Guided Therapies into the Ultrasound segment, now called Advanced Visualization Solutions, and has provided recast historical financials to reflect this change.

GE HealthCare's third-quarter results show modest revenue growth and improved profitability, leading to an increase in the lower end of their full-year adjusted EBIT margin and adjusted EPS guidance.

GE HealthCare has announced the pricing of a secondary offering of 15 million shares of its common stock at $86.00 per share, with no proceeds going to the company.

GE HealthCare Technologies has successfully issued $1 billion in senior unsecured notes due in 2029, with a 4.800% interest rate.

GE HealthCare has commenced and priced a $1 billion offering of senior notes due in 2029.

GE HealthCare announced flat year-over-year revenue and updated its full-year guidance due to challenges in the China market, despite margin expansion and solid orders growth in the U.S.

GE HealthCare Technologies Inc. successfully held its annual meeting on May 21, 2024, electing ten directors, approving executive compensation, and ratifying the appointment of Deloitte & Touche LLP as its independent auditor.

GE HealthCare's first quarter 2024 results show flat organic revenue growth and improved margins, with the company reaffirming its full-year guidance.